drugset / Trial / NCT00347295

Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.

NCT00347295

Phase 3 Completed 253 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the efficacy and safety of Brotizolam in the treatment of patients with insomnia in comparison with that of Estazolam

Timeline

Start
2006-06
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Brotizolam Small molecule 0.25 mg
Subject Estazolam Small molecule 1 mg
Subject Estazolam Small molecule 2 mg